Rallybio Corporation (NasdaqCM: RLYB) Loss Submission Form

Kuznicki Law is investigating the proposed merger of Rallybio Corporation (NasdaqCM: RLYB) and Avenzo Therapeutics, Inc. Upon completion of the proposed transaction, pre-Transaction Rallybio equityholders are expected to own approximately 2.8% of the combined company. Kuznicki Law is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger is fair to Rallybio shareholders.